A PD-1 Inhibitor Induces Complete Response of Advanced Bladder Urothelial Carcinoma: A Case Report

被引：6
|
作者：
Wang, Jianzheng [1 ]
Li, Qingli [2 ]
Lv, Huifang [1 ]
Nie, Caiyun [1 ]
Chen, Beibei [1 ]
Xu, Weifeng [1 ]
Yang, Tiejun [3 ]
Zhang, Yinping [4 ]
Tu, Shuiping [2 ]
Chen, Xiaobing [1 ]
机构：
[1] Zhengzhou Univ, Dept Med Oncol, Affiliated Canc Hosp, Henan Canc Hosp, Zhengzhou, Peoples R China
[2] Shanghai Jiao Tong Univ, Renji Hosp, Sch Med, Dept Oncol, Shanghai, Peoples R China
[3] Zhengzhou Univ, Henan Canc Hosp, Dept Urol Surg, Affiliated Canc Hosp, Zhengzhou, Peoples R China
[4] Zhengzhou Univ, Henan Canc Hosp, Dept Pathol, Affiliated Canc Hosp, Zhengzhou, Peoples R China
来源：
FRONTIERS IN ONCOLOGY | 2021年 / 11卷
关键词：
PD-1; complete response; advanced; urothelial carcinoma; case report; CELL LUNG-CANCER; ADVERSE EVENTS; PNEUMONITIS; CHEMOTHERAPY; GEMCITABINE; CISPLATIN; TOXICITY; EFFICACY;
D O I：
10.3389/fonc.2021.671416
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
The prognosis of patients with advanced urothelial carcinoma is dismal. Platinum-based chemotherapy is still the main first-line treatment for advanced urothelial carcinoma, while immunotherapy can be used as a first-line treatment option for people who cannot tolerate platinum. Immunotherapy is preferred in the second-line treatment of bladder urothelial carcinoma. PD-1 inhibitors (Pembrolizumab, nivolumab and atezolizumab) and PD-L1 inhibitors (Ddurvalumab and avelumab) have not been approved for the treatment of advanced urothelial cancer in China. We describe a patient with advanced urothelial carcinoma experienced disease progression after gemcitabine chemotherapy. Following a treatment of domestic PD-1 inhibitor (sintilimab), the patient achieved a durable complete response with mild toxicity. This case indicates that PD-1 inhibitor sintilimab might be a second-line treatment choice for advanced urothelial carcinoma.
引用
收藏
页数：7
相关论文
共 50 条
  • [41] Advanced ampullary carcinoma showing complete response to S-1: Report of a case
    Abe, Nobutsugu
    Sugiyama, Masanori
    Mizuno, Hideaki
    Suzuki, Yutaka
    Masaki, Tadahiko
    Mori, Toshiyuki
    Atomi, Yutaka
    SURGERY TODAY, 2010, 40 (06) : 574 - 577
  • [42] Pulmonary NUT carcinoma, an elusive and refractory entity, shows transient response to chemotherapeutics and PD-1 inhibitor: a case report and literature review
    Yang, Guangjian
    Liu, Runze
    Yang, Linke
    Yang, Xue
    Tang, Xiaoyong
    Mao, Huiqing
    FRONTIERS IN IMMUNOLOGY, 2025, 16
  • [43] Urothelial carcinoma of the bladder with trophoblastic differentiation: A case report
    Tuna B.
    Yörükoǧlu K.
    Mungan U.
    Kirkali Z.
    International Urology and Nephrology, 2004, 36 (4) : 529 - 531
  • [44] Y-90 Radioembolization Combined with a PD-1 Inhibitor for Advanced Hepatocellular Carcinoma
    Wehrenberg-Klee, Eric
    Goyal, Lipika
    Dugan, Matthew
    Zhu, Andrew X.
    Ganguli, Suvranu
    CARDIOVASCULAR AND INTERVENTIONAL RADIOLOGY, 2018, 41 (11) : 1799 - 1802
  • [45] Y-90 Radioembolization Combined with a PD-1 Inhibitor for Advanced Hepatocellular Carcinoma
    Eric Wehrenberg-Klee
    Lipika Goyal
    Matthew Dugan
    Andrew X. Zhu
    Suvranu Ganguli
    CardioVascular and Interventional Radiology, 2018, 41 : 1799 - 1802
  • [46] Clinical observation of PD-1 inhibitor combined with anlotinib in the treatment of advanced neuroendocrine carcinoma
    Song, L.
    Yu, X.
    JOURNAL OF NEUROENDOCRINOLOGY, 2021, 33 : 155 - 155
  • [47] Cutaneous metastasis of bladder urothelial carcinoma: a case report
    Gunel, H.
    Soylemez, T.
    Simsek, B. Cobanoglu
    VIRCHOWS ARCHIV, 2020, 477 : S249 - S250
  • [48] Primary exophytic urothelial carcinoma of the bladder: A case report
    Li, Liangliang
    Liu, Kun
    Ma, Xueping
    Wu, Yameng
    Wang, Changxi
    Wang, Yangang
    MEDICINE, 2024, 103 (32)
  • [49] Pulmonary pleomorphic carcinoma treated with PD-1 inhibitor: Two case reports
    Jiang, Tao
    Wang, Hao
    Xue, Fei
    Wu, Xuanpeng
    Ni, Ming
    Wang, Yuanyuan
    Chen, Nanzheng
    Zhang, Yong
    Zhang, Guangjian
    Fu, Junke
    Liu, Xi
    Wu, Qifei
    THORACIC CANCER, 2023, 14 (32) : 3240 - 3244
  • [50] Response to single agent PD-1 inhibitor after progression on previous PD-1/PD-L1 inhibitors: a case series
    Martini, Dylan J.
    Lalani, Aly-Khan A.
    Bosse, Dominick
    Steinharter, John A.
    Harshman, Lauren C.
    Hodi, F. Stephen
    Ott, Patrick A.
    Choueiri, Toni K.
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2017, 5
12345